Black Diamond Therapeutics (BDTX) Share-based Compensation (2019 - 2026)

Black Diamond Therapeutics' Share-based Compensation history runs 8 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• Quarterly Share-based Compensation fell 14.88% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 39.94% YoY) and the FY2025 annual result came in at $6.6 million, down 37.63% from the prior year.
• Share-based Compensation was $1.4 million for Q1 2026 at Black Diamond Therapeutics, up from $1.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $5.3 million in Q2 2024 and bottomed at $1.4 million in Q4 2025.
• A 5-year average of $2.4 million and a median of $2.0 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation surged 99.77% — and 2025, when it slumped 66.38%.
• Black Diamond Therapeutics' Share-based Compensation stood at $2.9 million in 2022, then sank by 47.14% to $1.5 million in 2023, then gained by 6.51% to $1.6 million in 2024, then declined by 13.69% to $1.4 million in 2025, then advanced by 2.48% to $1.4 million in 2026.
• Business Quant data shows BDTX's Share-based Compensation at $1.4 million in Q1 2026, $1.4 million in Q4 2025, and $1.7 million in Q3 2025.